Desloratadine

Introduction Overview

Generic Name

desloratadine

Brand Name

Clarinex, Clarinex Reditabs, Aerius

Dosage Form

oral tablet (5 mg), oral tablet disintegrating (2.5 mg; 5 mg)

Drug Class

Antihistamines

Pharmacokinetics

Absorption: Desloratadine exhibits rapid and almost complete absorption following oral administration, with peak plasma concentrations generally achieved within 3 hours. The bioavailability is high and unaffected significantly by food intake, allowing flexible administration with or without meals. Factors such as gastrointestinal pH and motility minimally influence absorption, providing a consistent pharmacokinetic profile across various patient populations. Extensive clinical studies have confirmed the predictable absorption kinetics, supporting once-daily dosing.

Distribution: After absorption, desloratadine is widely distributed throughout the body, demonstrating a large volume of distribution consistent with its high lipid solubility. Approximately 82-87% of desloratadine binds to plasma proteins, primarily albumin, which influences its distribution and half-life. Desloratadine crosses minimal amounts into the central nervous system, correlating with its low sedative potential compared to first-generation antihistamines. The tissue distribution supports its prolonged effect on peripheral H1-receptors responsible for allergic symptoms.

Metabolism: Desloratadine is extensively metabolized in the liver, primarily via cytochrome P450 enzymes, including CYP2C8 and CYP3A4 isoforms. It undergoes oxidative metabolism to produce 3-hydroxydesloratadine, which retains pharmacological activity. This metabolite contributes to the overall antihistaminic effect and prolongs the duration of action. Drug interactions affecting CYP enzymes can alter desloratadine metabolism, though clinically significant interactions are uncommon due to its metabolic pathways.

Elimination: The elimination half-life of desloratadine is approximately 27 hours in healthy adults, facilitating once-daily dosing. It is excreted via both renal and fecal routes, with about 75% eliminated in urine and the remainder in feces, mainly as metabolites. Renal clearance is a significant elimination pathway, but dose adjustment is generally not required in mild to moderate renal impairment. Liver impairment may modestly affect elimination, warranting cautious use. The prolonged half-life ensures sustained antihistaminic activity over 24 hours, supporting symptom control with once-daily administration.

Dosage Forms

Available Dosage Forms:
- Oral tablet: 5 mg
- Oral disintegrating tablet: 2.5 mg, 5 mg

Dosages for Adults and Adolescents:
- Adults and adolescents (12 years and older): 5 mg orally once daily for allergic rhinitis and chronic idiopathic urticaria

Specific Patient Populations:
- Pediatric patients 6 to 11 months: 1 mg orally once daily
- Pediatric patients 12 months to 5 years: 1.25 mg orally once daily
- Pediatric patients 6 to 11 years: 2.5 mg orally once daily

Clinical Considerations:
- Desloratadine can be administered with or without food, enhancing patient compliance.
- The orally disintegrating tablets should be placed on the tongue to dissolve without chewing, suitable for patients with swallowing difficulties.
- Pediatric dosing emphasizes lower doses adjusted by age to maintain safety and efficacy.
- Not recommended for children under 6 months of age due to insufficient data.
- Dosing regimens are designed to cover 24-hour symptom control for both seasonal and perennial allergic rhinitis, and chronic urticaria.

Mechanism Of Action

Desloratadine is a long-acting tricyclic antihistamine and selective peripheral H1-receptor antagonist. It exerts its therapeutic effects primarily by competitively inhibiting the binding of histamine to H1-receptors located on the surface of cells in the respiratory tract, skin, and other tissues involved in allergic reactions. By blocking these receptors, desloratadine prevents the cascade of allergic mediator release responsible for symptoms such as sneezing, nasal congestion, pruritus, and urticaria.

At the molecular level, desloratadine selectively targets peripheral H1-histamine receptors without significant penetration of the central nervous system, thereby minimizing sedation and other CNS adverse effects common to first-generation antihistamines. This selectivity is attributed to its minimal crossing of the blood-brain barrier, enhancing its safety profile for daily use.

The drug's action extends to stabilizing mast cells and impeding the release of additional pro-inflammatory mediators such as leukotrienes and prostaglandins, which contribute to tissue inflammation and edema in allergic responses. This biochemical interaction supports desloratadine’s efficacy in reducing both early and late-phase allergic symptoms.

Comparatively, desloratadine is an active metabolite of loratadine but demonstrates improved receptor binding affinity and a longer half-life. Clinical studies confirm superior efficacy in symptom relief and sustained action over 24 hours. These properties contribute to improved patient adherence and symptom control in chronic allergic conditions.

Pharmacological Actions

Selective peripheral histamine H1-receptor antagonist activity
Inhibition of histamine-induced allergic inflammatory responses
Reduction in nasal and non-nasal symptoms of allergic rhinitis including sneezing, itching, and rhinorrhea
Alleviation of pruritus and reduction of hives in chronic idiopathic urticaria
Minimal penetration of the blood-brain barrier resulting in negligible sedative effects
Sustained 24-hour antihistaminic effect allowing once-daily dosing
Stabilization of mast cells preventing release of additional inflammatory mediators
Active metabolite of loratadine with enhanced efficacy and longer duration of action
Non-sedating profile improving patient compliance
No significant anticholinergic or cardiac conduction effects

Therapeutic Or Clinical Uses

Relief of nasal and non-nasal symptoms of seasonal allergic rhinitis (e.g., sneezing, nasal congestion, itchy and watery eyes)
Treatment of perennial allergic rhinitis symptoms
Symptomatic relief of pruritus associated with allergic skin conditions
Management of chronic idiopathic urticaria by reducing number, size, and itching of hives
Adjunct therapy in allergy-driven dermatologic conditions requiring antihistaminic control
Safe once-daily treatment option for adult and pediatric patients six months and older with allergic rhinitis
Relief of allergic symptoms without sedation, allowing use in patients requiring alertness
Supportive therapy in allergic conjunctivitis when systemic antihistamine therapy is indicated
Potential off-label use in other histamine-mediated allergic reactions under clinical discretion
Treatment adherence enhanced by convenient oral dosage forms including disintegrating tablets

Side Or Adverse Effects

Dry mouth – frequently reported, attributed to antihistaminic drying effects
Sore throat – mild to moderate pharyngitis has been observed
Muscle pain – myalgia reported in some patients during therapy
Drowsiness and tiredness – generally mild and less common than first-generation antihistamines
Menstrual pain – some women report dysmenorrhea during treatment
Headache – occasional reports without clear dose-relationship
Fatigue – mild and transient in nature
Nausea – infrequent gastrointestinal disturbance
Abdominal discomfort – including mild dyspepsia
Rare hypersensitivity reactions including rash, pruritus, and urticaria
No significant cardiac or anticholinergic side effects identified in clinical use
Rare cases of elevated liver enzymes reported, warranting monitoring in hepatic impairment
Possible exacerbation of pre-existing renal or hepatic dysfunction
Minimal CNS depressant effect, but caution advised when used with other CNS-active drugs
No substantial reports of photosensitivity or carcinogenicity

Precautions

Avoid use in patients with known hypersensitivity to desloratadine or loratadine
Caution in individuals with hepatic impairment due to altered metabolism
Use cautiously in patients with renal dysfunction, monitoring for side effects
Inform healthcare provider if pregnant or breastfeeding prior to initiation
Contains phenylalanine; not suitable for patients with phenylketonuria (PKU)
Not recommended for children younger than 6 months old due to lack of safety data
Patients should report any signs of allergic reactions including swelling or breathing difficulty immediately
Proper measurement of syrup formulations is critical to avoid dosing errors
Patients with a history of cardiovascular diseases should use under medical supervision
Concomitant use with other central nervous system depressants should be monitored
Adherence to prescribed dosage is important; do not double dose after missed dose
Storage at room temperature away from moisture and light preserves drug stability
Avoid sharing medication with others to prevent unmonitored adverse events
Patients should disclose all other medications including OTC, herbal, and vitamins to check for interactions
Use with caution in patients with cholestasis or biliary obstruction

Warnings

Do not use desloratadine if allergic to desloratadine or loratadine
Follow all package and label directions strictly to avoid overdose
Seek immediate medical help if symptoms of severe allergic reaction occur, such as facial swelling or difficulty breathing
Use caution if hepatic or renal impairment is present as drug clearance may be affected
Not studied adequately in pregnant or breastfeeding women; use only if benefits outweigh risks
Avoid use in children under 6 months due to insufficient safety data
Use with caution in patients with phenylketonuria due to phenylalanine content in certain formulations
Concomitant administration with drugs that inhibit CYP enzymes (e.g., ketoconazole, erythromycin) may increase desloratadine levels
Possible additive effects if combined with other antihistamines or CNS depressants
Do not take two doses simultaneously if a dose is missed to prevent toxicity
Alert healthcare providers of all current medications to prevent unintended interactions
Avoid alcohol consumption during treatment to prevent exacerbated CNS side effects
Patients should be cautious driving or operating machinery until individual response is known
Use with caution in patients with pre-existing cardiac conditions due to limited data
Monitor for any unexpected adverse events and report to healthcare professionals promptly

Contraindication

Hypersensitivity to desloratadine
Allergy to loratadine or any components of the formulation
Children under 6 months of age due to lack of established safety and efficacy
Known phenylketonuria when using formulations containing phenylalanine
Patients with severe hepatic impairment without close medical supervision
Concurrent use with other long-acting antihistamines due to risk of additive toxicity
Known history of severe allergic reactions to antihistamines
Use contraindicated in patients with documented hypersensitivity to excipients of the tablets or syrup
Avoid use during lactation except when clearly needed and under medical advice
Patients with a history of drug-induced arrhythmias should avoid use without specialist consultation
Contraindicated in individuals with prior anaphylactic episodes to desloratadine

Drug Interactions

Concomitant use with ketoconazole can increase desloratadine plasma concentrations via CYP3A4 inhibition
Erythromycin administration may raise desloratadine levels by inhibiting metabolism
Azithromycin interaction potential though less inhibitor effect; caution advised
Fluoxetine may affect desloratadine metabolism leading to elevated levels
Cimetidine, a known CYP450 inhibitor, can increase desloratadine exposure
No significant interactions observed with common decongestants or nasal corticosteroids
Limited risk of pharmacodynamic interactions with CNS depressants due to low sedative effects
Concurrent use with other antihistamines may potentiate adverse effects
Caution advised when combining with alcohol or sedative-hypnotics
Potential interactions with herbal supplements that affect CYP450 enzymes, e.g., St. John's Wort
No significant interaction with antacids; dosing flexibility maintained
No significant effect on the metabolic clearance of oral contraceptives documented
Close monitoring when prescribed alongside QT-prolonging agents though desloratadine is low risk
Dose adjustment typically not required with renal or hepatic impairment when used cautiously
Patients advised to inform clinicians of all medications to prevent unrecognized interactions

Preparations Of The Drug

Desloratadine oral tablets: 5 mg strength for once-daily administration
Orally disintegrating tablets available in 2.5 mg and 5 mg doses, suitable for patients with swallowing difficulties
Desloratadine syrup preparations for pediatric use with measured dose syringes to ensure accurate dosing
Tablets formulated for rapid dissolution, ensuring prompt onset of action
Packaged to protect from moisture and light to preserve stability
Phenylalanine-containing formulations clearly labeled to alert patients with PKU
Manufactured following Good Manufacturing Practice (GMP) standards with consistent quality control
Single-dose and multi-dose packaging options available for outpatient compliance
Storage recommended at controlled room temperature between 20–25°C (68–77°F)
Formulations free from common allergens such as gluten and lactose for sensitivity management
Available through prescription and certain over-the-counter markets depending on country regulations
Manufactured both as branded (Clarinex, Aerius) and generic products
Orally disintegrating tablets designed for ease of administration without water
Liquid formulations calibrated for pediatric dosing convenience and safety
No noted preservatives in formulations intended for sensitive patient populations